For obesity treatment, another agonist of MC4r, PL-8905 (a cyclic peptide), also shows high selectivity for this receptor over MC1r, presents minimal side effects on blood pressure, and has significant chemical and metabolic stability [81]. This evidence concerns the gene MC4R and obesity disorder.